Jaguar Health, Inc. (JAGX) Earnings Call Transcript & Summary
May 26, 2026
What were the key takeaways from Jaguar Health, Inc.'s May 26, 2026 earnings call?
In the first quarter of 2026, Jaguar Health, Inc. reported a staggering 816% increase in net revenue to approximately $20.2 million, driven by a licensing agreement with Future Pak for Mytesi and Canalevia-CA1. The company also achieved a significant turnaround in income from operations, moving from a loss of $9.4 million in Q1 2025 to an income of $10.2 million in Q1 2026. Management maintained a strategic focus on advancing its intestinal failure program, with a new drug application (NDA) submission anticipated in mid-2027, signaling strong future growth potential.
What topics did Jaguar Health, Inc. cover?
- Revenue Surge: Jaguar reported net revenue of approximately $20.2 million for Q1 2026, an increase of 816% year-over-year and 527% sequentially. This surge was attributed to the licensing agreement with Future Pak, which allowed Jaguar to focus on its development programs.
- Operational Profitability: The company achieved income from operations of $10.2 million, a significant improvement from a loss of $9.4 million in the same quarter last year. This turnaround was largely due to license revenue and reduced operating expenses.
- Intestinal Failure Program Focus: Jaguar is concentrating on its pivotal stage program for a novel formulation of crofelemer aimed at treating rare intestinal failure indications. Management highlighted the potential NDA submission in mid-2027 for pediatric microvillus inclusion disease (MVID).
- Market Opportunity: Management emphasized the substantial market potential for their intestinal failure program, estimating the global market for short bowel syndrome (SBS) to reach approximately $8 billion by 2033. This positions Jaguar for significant future revenue growth.
- License Agreement Details: The licensing agreement with Future Pak is royalty-free and directs all revenue from Mytesi and Canalevia-CA1 to Future Pak, which allows Jaguar to focus its resources on developing its pipeline products.
What were Jaguar Health, Inc.'s May 26, 2026 results?
- Net Revenue: $20.2 million (vs $2.2 million in Q1 2025, +816% YoY)
- Income from Operations: $10.2 million (vs loss of $9.4 million in Q1 2025)
- Net Loss: $7.1 million (vs $10.5 million loss in Q1 2025)
- Prescription Products Revenue: $1.2 million (vs $2.2 million in Q1 2025, -45% YoY)
- Non-GAAP Recurring EBITDA: $6.4 million loss (vs $9.7 million loss in Q1 2025)
- Interest Expense: $700,000 (vs $56,000 in Q1 2025)
Jaguar Health's strong revenue growth and operational turnaround position it favorably for future investment. The focus on the intestinal failure program presents significant growth opportunities, but investors should monitor the sustainability of revenue streams and rising costs associated with interest expenses.
Earnings Call Speaker Segments
Oh, thank you so much. Good morning, everyone, and thanks for tuning in to our investor webcast today. I hope everybody enjoyed a wonderful holiday weekend. I'm Lisa Conte, and I serve as Founder, President, and CEO of Jaguar Health, along with our wholly-owned subsidiary Napo Pharmaceuticals; I also hold the Chairman role at our Italian subsidiary, Napo Therapeutics. As I typically do, I might refer to Jaguar and Napo interchangeably when talking about our company. Once I've finished, Carol Lizak, our CFO, will walk through a recap of the financial highlights from Q1 of 2026. Transformation and sharp strategic focus — that's the theme for today's webcast. Before Carol speaks, I want to step in with some good news: our company's net revenue climbed 816% when you compare the first quarter of 2026 to the same period in 2025, and it increased 527% versus the fourth quarter of 2025. Driving this was a game-changing U.S. out-license deal we signed in January 2026 with Future Pak covering Mytesi, our crofelemer tablet version cleared by the FDA for adults with HIV/AIDS who suffer from diarrhea. That license also covered Canalevia-CA1, our crofelemer formulation for dogs that holds conditional approval. Our first move was a strategic one: we decided to out-license both Mytesi and Canalevia-CA1 to Future Pak. The reason is that they had just bought Theratechnologies, a commercial company focused on HIV, whose U.S. commercial effort is over four times larger than Jaguar's. The second reason was to carry out our strategic plan of bringing in significant non-dilutive dollars, which would fund a tight development focus on our pivotal stage program involving our novel proprietary powder for oral solution formulation of crofelemer. This is a different formulation from the Mytesi tablets. That powder for oral solution formulation of crofelemer targets rare intestinal failure indications. Our strategy carries on, with the aim of finding a development and commercialization partner for this program too. On this call, I want to walk through what's driving near-term value in our intestinal failure development program. The lead indication we're targeting is pediatric microvillus inclusion disease, or MVID. It's an ultra-rare condition, and there are currently no approved therapies for it. We've started down a clinical path that we expect will lead to a potential NDA submission in mid-2027 — that's a new drug application filed with the FDA. Then there's short bowel syndrome, which I'll call SBS. When it involves intestinal failure, we refer to it as SBS-IF, and that's a larger follow-on indication. It uses the same dosage form, which differs from Mytesi tabs. To repeat, it's the same powder that becomes a liquid, and it works through the same physiological mechanism as intestinal failure in MVID patients. When it comes to tackling this devastating unmet medical need in patients facing a fatal disease course, our intestinal failure program is a blockbuster global market opportunity. It's blockbuster in how much it can improve morbidity, mortality, and healthcare system costs, and it's blockbuster as a financial return opportunity for every stakeholder — something that matters especially to a potential corporate partner. As an illustration, one third-party market research study projects that by 2033, the worldwide short bowel syndrome market — which includes short bowel syndrome with intestinal failure — will reach approximately $8 billion, and a separate third-party valuation puts the global MVID marketplace at more than $1 billion. Let me pause and convey what intestinal failure does to patients, to those who care for them, and to the providers, physicians, nurses, dietitians, relatives, and everyone else engaged in that caregiving. This condition is devastating and frequently means patients depend on life-sustaining fluids, electrolytes, and nutrients delivered intravenously — that is total parenteral nutrition, or TPN, plus supplemental intravenous fluids, together known as parenteral support, PS. A large number of these patients need parenteral support as often as seven days each week, and at times 20 hours per day or beyond. Clearly devastating, with no quality of life. Parenteral support keeps people with intestinal failure alive, but it comes with serious downsides. It often causes major health problems, including issues with how the liver and kidneys work, metabolic complications, infections, cognitive impairment, and in children, significant impairment of growth. These symptoms often become life-threatening. In the United States, PS costs about $500,000 per year, and when you add in the complications that can't be avoided, the healthcare system may bear more than $1 million annually for each patient. For IF patients receiving parenteral support, the main benefit — and the primary endpoint in clinical development — is the opportunity to reduce PS by as little as 10% to 15%. Take, for example, the benefit of allowing someone receiving PS to get most of it during the night while sleeping, so they can retain a decent quality of life when awake. Picture as well a kid attending school without being tethered to an IV line for parenteral support. Last year, in November 2025, initial breakthrough findings were presented at NASPGHAN from the independent, ongoing proof-of-concept study of crofelemer involving pediatric patients in the U.A.E., the United Arab Emirates, suffering from intestinal failure due to MVID and SBS-IF. NASPGHAN is shorthand for the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition — quite a mouthful, that acronym. The presentation at that yearly gathering was given by the study's primary investigator. Those initial findings show disease progression modification from crofelemer via parenteral support reduction in pediatric intestinal failure patients, ranging from 12%-37%. To be specific, among the two pediatric IF patients who finished treatment, the data revealed crofelemer lowered parenteral support by between 12.5% and 15.6%; for the MVID patient, once more, who has no alternative treatment, parenteral support requirements dropped by as much as 37%. Worth repeating — 37%, an extraordinary outcome. Several patients with intestinal failure from either MVID or SBS participating in the U.A.E. trial have now received treatment for over one year. More data covering a longer time frame is going to be shared at the yearly ESPGHAN meeting — that's another tongue-twister — the European one, not the North American one, meaning the European Society for Paediatric Gastroenterology, Hepatology and Nutrition, taking place in June 2026. There's also one more MVID infant receiving oral crofelemer through an FDA-authorized expanded access program, and information on how safe and effective crofelemer is for this baby will be shared at the ESPGHAN conference too. It's a really interesting case: this patient, a very young baby, got an MVID diagnosis immediately after being born and was too little to join our clinical trial, which I'll discuss shortly. Thanks to the expanded access to crofelemer, the child has reached nine months of age and is thriving at the 27% growth curve, despite what is otherwise a devastating diagnosis with a fatal natural course. Crofelemer has been tolerated well, and the pediatric MVID patients are putting on weight and height while showing decreases in what they need for parenteral support each day and each week. No safety problems tied to crofelemer have appeared in intestinal failure patients, which lines up with how safe crofelemer has proven to be across thousands of patients in trials for other conditions and through years on the market as an FDA-approved treatment for HIV-related diarrhea. Our expectation is that the pediatric intestinal failure patients in these ongoing programs will keep getting crofelemer from the company for the remainder of their lives. That makes us very proud.
Meanwhile, a pivotal trial is underway — randomized, double-blind, and placebo-controlled — to evaluate the safety and efficacy of crofelemer's liquid form in pediatric individuals suffering from intestinal failure attributable to MVID. All participants have now been enrolled. With an eye toward submitting an NDA, or new drug application, to the FDA using data from these patients, Napo filed an amendment and secured the agency's agreement for a treatment-only extension portion of the study. That treatment-only extension has begun, with the first MVID patient now taking part, and it is active at clinical locations throughout the United States, Italy, and the U.A.E. We expect that within the next couple of months, the rest of the enrolled patients will move into the treatment-only portion, once every site involved gives the go-ahead to add to what the FDA has already acknowledged. If you add up those in the blinded study along with the MVID patients taking part in expanded access and the investigator-initiated studies — the data we'll be sharing at ESPGHAN next month — our estimate is that we're providing treatment to about 4% of all patients worldwide living with this ultra-rare condition, MVID. As you can likely tell from what you're hearing, we feel strongly and are deeply committed to securing crofelemer's approval as quickly as possible so that every MVID patient can benefit. When it comes to approving any drug, what matters is the balance between benefit and risk. Studies in patients have demonstrated crofelemer carries no danger and is very well tolerated, and the advantages when it comes to lowering PS, especially in relation to body weight among pediatric patients who are still growing, are self-evident. In our view, this amounts to a strong outcome, providing a breakthrough add-on treatment that cuts down the need for PS support as well as the related toxicities associated with that life-saving PS. Considering the ultra-rare nature of MVID — once more, an illness lacking any approved therapies — and given the ongoing benefits we observe, we aim to obtain breakthrough therapy designation from the FDA for crofelemer so that U.S. We're pushing the regulatory route to market even harder. On top of that, we have our sights set on possible EMA pathways — that's the European Medicines Agency, which plays the same role in Europe that the FDA does here — to speed up approval and get to market throughout all 27 EU nations. If we secure a breakthrough designation in the US, the approval timeline comes down to four months. And as I noted earlier, our crofelemer intestinal failure programs get an extra boost from clinical proof-of-concept data gathered in pediatric patients whose intestinal failure stems from short bowel syndrome, or SBS. The oral liquid version of crofelemer is a drug candidate that isn't a growth hormone, intended as adjunctive therapy alongside parenteral support, working through a first-in-class physiological mechanism that's unlike anything else — it cuts liquid stool output, which in turn lowers the need for parenteral support. Crofelemer works right in the gut as a modulator of intestinal chloride ion channels, cutting down the fluid buildup that chloride drives. Picture osmosis at work. When chloride pulls fluid into the GI tract, that accumulation gets reduced, which means patients lose less fluid and fewer electrolytes, and their need for parenteral support drops along with it. That's an endpoint with real clinical meaning. In both MVID and SBS-IF, the benefit we offer is a lower requirement for parenteral support — and for these patients, no other option exists apart from lifelong parenteral support that keeps them alive, which carries high rates of comorbidities and often proves fatal. We currently have underway a phase II trial that is randomized, double-blind, and placebo-controlled, testing the liquid form of crofelemer — the identical formulation used in MVID — in adults with SBS-IF, running at a number of sites across Germany and Italy. SBS-IF impacts a patient population substantially bigger than MVID does, even though it remains an orphaned indication, and it comes about from congenital anomalies or surgical resection tied to conditions such as Crohn's disease, mesenteric ischemia, cancer, and trauma. Adults and pediatric patients with SBS-IF deal with chronic reliance on parenteral support because their intestines lack enough absorptive surface area. In the U.S., the SBS-IF patient population is put at 12,500 patients. Regarding crofelemer for MVID, our target is to submit a new drug application around the middle of 2027. That timing coincides with when we anticipate data from our blinded phase II trials in adults who have SBS-IF. Because the same IF formulation is involved, this approach provides a CMC stepping stone toward the regulatory path we've mapped out for securing approval eventually in short bowel syndrome. Conversations about business development are currently taking place and encompass our entire IF program. More precisely, we seek a collaborator to support funding the remaining development work and the commercialization of crofelemer for MVID and SBS-IF in territories outside the United States. We've shown that we're able to execute and finalize major non-dilutive business development transactions — much like the one we completed with Future Pak back in January. When that agreement closed in January, $16 million in non-dilutive dollars arrived upfront, and $2 million will be payable to Jaguar shortly after the post-concluding conditions are satisfied. Beyond that, the deal terms have brought us an additional $3 million in non-dilutive funding, along with continuing significant dollars tied to inventory purchases, which Jaguar buys at a profit. People estimate the intestinal failure market to be about 100 times the size of the HIV diarrhea market, so bear that in mind when you think about the magnitude of the business development deals we're going after in IF. With the clinical proof-of-concept results already in hand, plus the clinical and regulatory milestones we expect to hit soon, we have strong confidence in carrying out our business development objectives and strategy for the intestinal failure program. That puts us in a position to potentially secure significant non-dilutive funding that matches the size of the market, driven by a substantial unmet medical need. At this point I'll hand it over to Carol, who will walk through the financial highlights from the first quarter of 2026. Thanks, Carol.
Good morning, Lisa, and I appreciate everyone joining our webcast today. I'll start by walking through our financial results for Q1 2026. This performance was helped by the licensing of U.S. commercial rights for Mytesi and Canalevia-CA1 back in January 2026. Total net revenue across the company's prescription products — Mytesi, Gelclair, and Canalevia-CA1 — along with non-prescription products and license revenue came to roughly $22 million in the first quarter of 2026. That marks a rise of about 816% versus total net revenue in Q1 2025, which was approximately $2.2 million, and a gain of roughly 527% compared with total net revenue in Q4 2025, which came in at approximately $3.2 million. For the company's prescription products, total net revenue in Q1 2026 was approximately $1.2 million, with about $174,000 of that coming from Mytesi inventory sales during the first 11 days of Q1 2026. The rest of that $1.2 million in net revenue largely came from selling Mytesi inventory to Future Pak later in Q1 2026; during January 2026, as Lisa mentioned, Jaguar signed a royalty-free license agreement with Future Pak. Per that agreement, every dollar of revenue generated in the United States from Mytesi and Canalevia-CA1, effective January 12th, 2026, flows to Future Pak. This move is consistent with Jaguar's strategic emphasis on pushing forward development of its powder for oral solution formulation of crofelemer for rare disease indications tied to intestinal failure in humans. Net revenue from the company's prescription products fell 62% versus Q4 2025, when total net revenue for prescription products was approximately $3.2 million. On top of that, prescription products net revenue dropped by 45% in Q1 2026 relative to the same quarter of 2025, when total net revenue for prescription products reached approximately $2.2 million. Income from operations improved by $19.6 million, swinging from a loss of $9.4 million in the quarter ended March 31, 2025, to income of $10.2 million in the quarter ended March 31, 2026, driven mainly by license revenue recognized under the Future Pak agreement plus lower operating expenses. Non-GAAP recurring EBITDA for the first quarters of 2026 and 2025 was a net loss of $6.4 million and $9.7 million, respectively. Net loss attributable to common shareholders shrank by approximately $3.4 million, going from a loss of $10.5 million in the quarter ended March 31, 2025, to a loss of $7.1 million in the quarter ended March 31, 2026. Beyond the loss from operations, interest expense grew by $800,000, from $56,000 for the quarter ended March 31, 2025, to approximately $700,000 in the quarter ended March 31, 2026, because of interest expenses accrued on new notes. The fair value of the financial and hybrid instrument we designated under the fair value option, or FVO, went down by $1 million — from a $1.3 million loss in the quarter that closed March 31, 2025, to a $300,000 loss in the quarter that closed March 31, 2026. That move was driven mainly by fair value adjustments on liability classified loans and notes payable that carry the FVO designation. We recorded a $600,000 loss on extinguishment of debt in the three months that ended March 31, 2026, because of significant modifications that qualified for extinguishment accounting; nothing of that kind was recorded in the corresponding period of 2025. That wraps up my recap of the high-level financials for the first quarter of 2026. I'll now hand the discussion back to Lisa.
Appreciate that, Carol. Like I said earlier, we anticipate that our intestinal failure program will keep delivering clinical proof of concept milestones, and it's currently the topic of business development talks that could bring in non-dilutive funds from prospective licensee partners. A key point: crofelemer stands as the first and only oral prescription drug the FDA has approved under botanical guidance, which serves as a de facto and perpetual IP shield. Everyone across the Jaguar, Napo, and Napo Therapeutics family is still fully energized and thrilled about the many near-term catalysts we expect for crofelemer and the company — all of which, in our view, are significant, value-enhancing, transformative, and potentially transformative for patients as well as Jaguar; that wraps up our webcast for today. Thanks to each of you for joining, and have a wonderful week.
For developers and AI pipelines
Programmatic access to Jaguar Health, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.